AtaGenix Laboratories
AtaGenix combines its extensive expertise in protein production with a comprehensive toolbox to optimize your yeast protein expression.
Choose between several hosts
Choose between P. pastoris and S. cerevisiae for your protein expression.
Access a complete yeast expression toolbox
We propose different strains of P. pastoris or S. cerevisiae to optimize your protein production.
Unrivalled protein production expertise
With 1500+ protein expressions, you can trust our expertise.
Integrated solution from gene to protein
From optimized gene to protein, we are your protein expression partner!
PhD account managers
At AtaGenix, a PhD account manager assists you!
Cost-effective expression system
Yeasts are known for their fast growth rate and high yield protein expression.
Expression vector construction (optional)
- Gene design including codon optimization
- Gene synthesis
- Subcloning in an expression vector
Small-scale protein expression
- Transformation and selection of yeast clones
- Determination of top expressing clones
- Expression optimization
- SDS-page + WB if necessary
- Purification tests
Protein expression scale up and purification
- Protein expression and purification with optimized conditions previously determined.
Step | Content | Timeline | Deliverables |
Protein pilot | - Transformation of yeast cells - Selection of the best expressing clones - Protein expression - Optimization - Purification tests |
4 to 5 weeks | - Test protein sample |
Transient protein expression and purification | - Large scale protein expression - Purification - QC analysis: SDS-PAGE, concentration |
2 weeks | - Purified protein - Detailed report |
Optional needs including codon optimization for protein expression and subcloning in an expression vector
- Protein expression chromatography
- DNA, HPLC, endotoxins
- Analytics: WB, analytical SEC
A 2017 study developed a high-affinity anti-HE4 monoclonal antibody (9C3) using AtaGenix’s advanced mammalian expression and hybridoma platforms. This breakthrough enhances ovarian cancer diagnostics by targeting the HE4 biomarker with high specificity, offering potential for early detection and therapy.
This article highlights a 2021 Small Methods study that identified immunogenic peptides in the SARS-CoV-2 spike protein and isolated neutralizing monoclonal antibodies from COVID-19 patients. The research pinpointed key RBM epitopes (S431-454, S470-486, S501-515), with S470-486 emerging as an immunodominant target for diagnostics and therapeutics. Using phage display and ScFv libraries, the study validated epitope mapping and antibody functionality. Supported by AtaGenix’s expertise in phage display, protein expression, and assay development, this breakthrough offers a scalable approach for combating emerging viral pathogens, updated as of August 24, 2025.